Efficacy of ALK inhibitors on NSCLC brain metastases: A systematic review and pooled analysis of 21 studies

Fausto Petrelli¹*, Chiara Lazzari², Raffaele Ardito³, Karen Borgonovo¹, Alessandra Bulotta², Barbara Conti⁴, Mary Cabiddu¹, Jody Filippo Capitanio⁵, Matteo Brighenti⁶, Mara Ghiliardi¹, Luca Gianni², Sandro Barni¹, Vanesa Gregorc²

¹ Oncology Unit, Oncology Department, ASST Bergamo Ovest, Treviglio (BG), Italy, ² Oncology Unit, Department of Oncology, Division of Experimental Medicine, IRCCS San Raffaele, Milan, Italy, ³ Oncology Unit, IRCCS Centro di Riferimento Oncologico della Basilicata (CROB), Via Padre Pio 1, Rionero in Vulture (PZ), Italy, ⁴ Surgical Oncology Unit, Surgery Department, ASST Bergamo Ovest, Treviglio (BG), Italy, ⁵ Neurosurgery Unit, Department of Neurosurgery and Gamma Knife Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy, ⁶ Oncology Unit, Oncology Department, ASST Ospedale di Cremona, Viale Concordia 1, Cremona, Italy

* faupe@libero.it

Abstract

Background

Patients with anaplastic lymphoma kinase rearranged (ALK+) non-small cell lung cancer (NSCLC) have a higher risk of developing brain metastases (BMs) than patients with other NSCLC sub-types. ALK inhibitors have activity in BMs due to ALK+ NSCLC. We performed a systematic review of the literature with the aim of assessing the efficacy of ALK inhibitors on BMs.

Material and methods

A systematic search of the literature was performed using the databases Pubmed, EMBASE, Web of Science, The Cochrane Library, and SCOPUS. Relevant publications reporting activity of ALK inhibitors in NSCLC BMs were retrieved. Data were pooled using the number of events/number of evaluable patients according to fixed or random effect models. Intracranial tumour response was assessed through overall response rate (ORR), disease control rate (DCR: ORR + stable disease rate), median progression-free survival (PFS), and overall survival (OS). The primary endpoint was intracranial overall response rate (IC ORR).

Results

A total of 1,016 patients with BMs from 21 studies were analysed. In patients receiving ALK inhibitors in the first line setting, the pooled IC ORR was 39.17% (95%CI 13.1–65.2%), while the pooled IC ORR observed in further lines was 44.2% (95%CI 33.3–55.1%). Intracranial disease control rate (IC DCR) was 70.3% and 78.2% in naive and pre-treated patients, respectively. Patients who had not received brain radiation attained an IC ORR of 49.0%.
Conclusions
Based on these data, ALK inhibitors are effective in both naive and pre-treated patients with similar IC ORR and IC DCR, irrespective of the line of therapy.

Introduction
During the last ten years, the technological advances and the deeper knowledge of non-small cell lung cancer (NSCLC) biology have revolutionized the management of patients with NSCLC. The discovery of activating mutations in the epidermal growth factor receptor gene (EGFR) [1], and the identification of the gene rearrangement between echinoderm microtubule-associated protein like 4 and anaplastic lymphoma kinase (EML4-ALK) [2], have initiated the era of precision medicine in lung oncology, thus significantly improving survival in molecularly classified subsets of patients, who are amenable to targeted inhibition.

EML4-ALK translocations are observed in approximately 5% of NSCLC patients, mainly never or light smokers, with a median age of 52 years and adenocarcinoma histology [3]. ALK positive NSCLC patients have a high risk of developing brain metastases (BMs), as observed in at least 20% of cases at the time of the initial diagnosis, thus dramatically influencing patients’ quality of life and their prognosis [4]. Local therapies (surgical resection, stereotactic radio surgery, and whole brain radiotherapy) are generally used for the management of patients with BMs, since the central nervous system (CNS) is considered a pharmacological sanctuary, where the expression of drug-efflux transporters limits the blood-brain barrier penetration. The concomitant use of systemic tyrosine kinase inhibitors (TKIs) and local treatments prolong patients’ survival, as observed in a retrospective analysis, including 90 ALK positive NSCLC patients who reached a median overall survival (OS) of more than four years [5]. A double median survival was observed in TKI naive patients compared with those who developed BMs during treatment with ALK inhibitors. Ceritinib, alectinib, brigatinib, and lorlatinib have been designed to overcome the pharmacodynamic and pharmacokinetic crizotinib failure at brain site.

In the current paper, we performed a pooled analysis, including data from ALK positive NSCLC patients with BMs receiving ALK inhibitors. Patients were stratified according to the type of ALK inhibitors, the line of treatment, and if they had previously received radiotherapy or not. The intracranial activity of the different ALK Inhibitors and their influence on intracranial progression free survival (IC PFS) and OS was evaluated, as the effect of radiotherapy on intracranial objective response rate (IC ORR).

Methods
Search strategy and selection criteria
We have systematically searched PubMed (MEDLINE), EMBASE, The Cochrane Library, Scopus, and Web of Science for relevant prospective studies published between inception and 30th June 2017. The following keywords were used: alk [All Fields] AND (“lung neoplasms” [MeSH Terms]) OR (“lung”[All Fields] AND “neoplasms” [All Fields]) OR “lung neoplasms” [All Fields] OR (“lung”[All Fields] AND “cancer” [All Fields]) OR “lung cancer” [All Fields] OR (“carcinoma, non-small-cell lung” [MeSH Terms] OR (“carcinoma” [All Fields] AND “non-small-cell” [All Fields] AND “lung” [All Fields]) OR “non-small-cell lung carcinoma” [All Fields] OR “nsclc” [All Fields] AND (“brain metastases” [All Fields] OR “central nervous system metastases” [All Fields]).
Preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines were followed when planning, conducting, and reporting this meta-analysis (S1 Table).

The studies included had to satisfy the following criteria: (1) randomised control trials (RCTs), or prospective or observational studies; (2) ≥ 10 patients included; (3) enrollment of ALK positive NSCLC patients with BMs; (4) treatment with an ALK inhibitor. Case reports and series where the concomitant use of radiotherapy was permitted were excluded. Our search included journal articles written in English and non-English. Two reviewers independently determined study eligibility (FP and RA). Disagreements were resolved by consensus with a third author (CL).

**Statistical analysis**

For each study included in the meta-analysis, we computed the type of study, the total number of patients treated, the frequency of patients with BMs, the type of ALK inhibitor used, the use of local treatments, the ICC ORR, the IC PFS, the median progression free survival (PFS), the median OS, and the one-year OS. The primary endpoint was ICC ORR. We pooled data on ICC ORR and intracranial disease control rate (ICC DCR) that reflected the proportion of patients with complete response, partial response, or stable disease for at least 24 weeks. We employed the random-effect model as a conservative approach to account for different sources of variation among studies (i.e. within-study variance and between-study variance) [6].

Secondary endpoints were IC DCR, median PFS, median OS, and one-year OS. Dagra software was used to ascertain survival data by digitising figures if the information was not provided directly. Finally, we computed both Q and I² statistics in order to evaluate heterogeneity across studies. A significant Q value indicates the lack of homogeneity of results across studies. I² estimates the proportion of observed variance that reflects real differences in effect sizes.

First, we performed a subgroup analysis according to the line of therapy (first line vs. beyond). For each subgroup, a further analysis including race (Asiatic vs. others), previous radiotherapy (yes vs. no), and type of ALK inhibitor was performed. To check the stability of our findings, sensitivity analyses were conducted. We computed the ICC ORR changes by removing one study at a time.

Quality of trials was assessed by the Jadad scale for randomized controlled studies and using the Newcastle-Ottawa Scale (NOS) for retrospective cohort studies. The risk of bias for the studies included deemed to be eligible for the review was assessed independently by two review authors (FP and CL) using the Cochrane ‘Risk of bias’ assessment tool. Discrepancies were resolved by discussion. Trials were screened and analysed for the following risk of bias criteria: 1. Selection bias (random sequence generation and allocation concealment); 2. Performance bias (blinding of participants and personnel); 3. Detection bias (blinding of outcome assessment); 4. Attrition bias (incomplete outcome data); 5. Reporting bias (selective reporting), and 6. Other bias. To determine whether published studies had different results from unpublished studies, publication bias analyses using the Egger’s regression method and the Begg and Mazumdar’s rank correlation test were performed. In both tests, the absence of publication bias was indicated by non-significant results. Descriptive statistics (pooled mean and meta-analysis of proportions) were calculated with Comprehensive Meta-Analysis software, version 3 (Biostat, Inc.).

**Results**

Eight hundred and ninety eight publications were retrieved (Fig 1) and 21, which included data from 1,016 patients with ALK positive NSCLC and BMs, were analysed (range 7–275) (Table 1). Seven studies evaluated crizotinib [7–13], five ceritinib [14–18], four alectinib [19–
In patients receiving ALK inhibitors in the first line setting, data on IC ORR and IC DCR were available in three out of five studies analyzed. The pooled ICC ORR was 39.17% (95%CI 13.1–65.2%), and the pooled IC DCR was 70.3% (95%CI 47.7–86.0%), according to the random effect model (Fig 2). The ICC ORR observed in patients receiving alectinib was 59.0% (95%CI 29.3–83.0%), in those treated with ceritinib was 56.6% (95%CI 33.3–77.4%), and in those

**Intracranial overall response rate and disease control rate**

In patients receiving ALK inhibitors in the first line setting, data on IC ORR and IC DCR were available in three out of five studies analyzed. The pooled ICC ORR was 39.17% (95%CI 13.1–65.2%), and the pooled IC DCR was 70.3% (95%CI 47.7–86.0%), according to the random effect model (Fig 2). The ICC ORR observed in patients receiving alectinib was 59.0% (95%CI 29.3–83.0%), in those treated with ceritinib was 56.6% (95%CI 33.3–77.4%), and in those
receiving crizotinib was 26.0% (95%CI 8.9–55.9%). Analysis by race was not possible, as the majority of the trials analyzed were international multicentre or US studies.

In the pre-treated setting, 12 studies evaluated IC ORR and nine IC DCR. The pooled IC ORR observed was 44% (95%CI 33.3–55.1%), and the IC pooled DCR was 79% (95%CI 70–85.9%), according to the random effect model (Fig 3). The IC ORR observed in patients receiving alectinib was 52.4% (95%CI 34.1–70.1%), in those treated with brigatinib was 46.7% (95%CI 25.2–69.5%), in the group under ceritinib was 41.5% (95%CI 28–56%), and in those under

Table 1. Characteristics of included studies.

| Author/year | N’ of pts | Type of study | Country | ALK inhibitor | Previous local therapy % | Previous ALK inhibitor % | Previous CT % | IC ORR % | ORR criteria |
|-------------|-----------|---------------|---------|---------------|---------------------------|--------------------------|--------------|-----------|-------------|
| Bendaly 2017| 22        | Retrospective | USA     | Ceritinib     | -                         | 100                      | 20.7         | 70        | Recist §  |
| Costa 2015  | 22        | Phase 2/3     | Interna| Crizotinib    | 0                         | 0                       | 100          | 18        | Recist 1.1 |
| Costa 2015  | 18        | Phase 2/3     | Interna| Crizotinib    | 100                       | 0                       | 100          | 33        | Recist 1.1 |
| Crino 2016  | 25        | Phase 2       | Interna| Ceritinib     | 100                       | 100                     | 100          | 45        | -           |
| Davis 2017  | 23        | Retrospective | Europe  | Crizotinib    | 52                        | 69^                      | -            | 31.2**    | -           |
| Doherty 2017| 21        | Retrospective | Canada  | Crizotinib/Ceritinib | 95                        | 0                       | 0            | 0         | -           |
| Gadgeel 2014| 21        | Phase 1/2     | US      | Alectinib     | 81                        | 100                     | 95           | 52        | Recist 1.1 |
| Gadgeel 2016| 41        | Phase 2       | Interna| Alectinib     | 0                         | 100                     | 80           | 58.5      | Recist 1.1 |
| Gadgeel 2016| 95        | Phase 2       | Interna| Alectinib     | 100                       | 100                     | 80           | 35.8      | Recist 1.1 |
| Gettinger 2016* | 21 | Phase 1/2 | USA/Spain | Brigatinib | 0                        | 85                      | -            | 57.1      | Recist 1.1 |
| Gettinger 2016 | 46 | Phase 1/2 | USA/Spain | Brigatinib | 100                       | 91                      | -            | 41.3      | Recist 1.1 |
| Hong 2017   | 15        | Retrospective | China   | Crizotinib    | 66.7                      | 69.7^                   | -            | -         | Recist 1.1 |
| Johung 2010 | 90        | Retrospective | US      | Crizotinib (93%) | 93                        | -                       | -            | -         | Recist 1.1 |
| Kim 2016    | 94        | Phase 1       | Interna| Crizotinib    | 67                        | 80                      | -            | 23.4      | Recist 1.1 |
| Kim 2017    | 44^       | Phase 2       | Interna| Brigatinib    | -                         | 65                      | 74           | 52.2      | Recist 1.1 |
| Lei 2015    | 19        | Retrospective | China   | Crizotinib    | 0                         | 63.2                    | -            | 73.7      | Recist 1.1 |
| Lei 2015    | 19        | Retrospective | China   | Crizotinib    | 100                       | 63.2                    | -            | 63.2      | Recist 1.1 |
| Metro 2016  | 7         | Retrospective | Italy   | Alectinib     | 73                        | 100                     | -            | 85.7      | Recist 1.1 |
| Peters 2017 | 58        | Phase 3       | Interna| Crizotinib    | 37.9                      | 0                       | 0            | 26        | Recist 1.1 |
| Peters 2017 | 64        | Phase 3       | Interna| Alectinib     | 42.1                      | 0                       | 0            | 59        | Recist 1.1 |
| Shaw 2017   | 66        | Phase 3       | Interna| Crizotinib    | 56                        | 100                     | 100          | 35^**     | Recist 1.1 |
| Solomon 2016| 39        | Phase 3       | Interna| Crizotinib    | 100                       | 0                       | 0            | -         | Recist 1.1 |
| Soria 2017  | 54        | Phase 3       | Interna| Ceritinib     | 100                       | 0                       | 0            | 46.3      | Recist 1.1 |
| Soria 2017  | 32        | Phase 3       | Interna| Ceritinib     | 0                         | 0                       | 0            | 46.9      | Recist 1.1 |
| Tamura 2017 | 14        | Phase 1/2     | Japan   | Alectinib     | -                         | 0                       | 100          | -         | Recist 1.1 |
| Xing 2016   | 20        | Retrospective | China   | Crizotinib    | 60                        | 74                      | -            | 15        | -           |
| Yoshida 2016| 26        | Retrospective | Japan   | Crizotinib    | 50                        | 69^                     | -            | 20^'^     | Recist 1.1 |

*, subgroup analysis with no previous radiotherapy patients of the main study

^, only patients with measurable brain metastases

§, version not specified

IC ORR, overall response rate of brain metastases

** , only for second/later lines patients

^*, in 17 patients with measurable disease

^'^, in 10 patients with brain metastases present before crizotinib; CT, chemotherapy; US, United States of America

-, not reported.

https://doi.org/10.1371/journal.pone.0201425.t001
crizotinib was 35.3% (95%CI 17.9–57.8%). The efficacy of ALK inhibitors was not dependent by previous radiotherapy, as observed in meta-regression analysis (p = 0.64). Comparable results were found in Asiatic vs. western/international populations.

In an exploratory analysis, including five studies enrolling patients who had not previously received brain radiotherapy, the IC ORR was 49.0% (95%CI 27.3–71.1%). The pooled IC ORR, including data from patients who had undergone radiotherapy (range 14–100 of pre-treatment with radiotherapy) was 38.4% (95%CI 31.1–46.3%). However, meta-regression analysis did not find any significant difference in terms of IC ORR between patients who had previously received radiotherapy or not (p = 0.32).

Overall, IC DCR was 85.8% (95%CI 79.3–90.4%), 88.3% (95%CI 80.5–93.2%), 69.1% (95% CI 61.8–75.6%) and 71.2% (95%CI 51.7–85.1%) for alectinib, brigatinib, ceritinib and crizotinib, respectively.

**Intracranial progression free survival, median progression free survival, median overall survival, and one-year overall survival**

Median PFS in naive patients was 7.3 months (range 5.9–10.7), and median IC PFS was 13.2 months (range 7.0–15.7). Median OS was 23 months. Pooled one-year OS was calculated using data from two studies, and was 64.0% (range 59.0–81.0%).

In the pre-treated setting, median PFS was 8.0 months (range 4.4–38.0), and median IC PFS of 14.6 months (range 8.0–22.3). Median OS, available in two studies, was 23.0 months. Pooled one-year OS, using data from four studies, and was 71.4% (range 31.0–76.2%).
Publication bias

Quality of trials and risk of bias according to the Cochrane ‘Risk of bias’ are reported in Table 2. No evidence of bias was observed (Begg’s funnel plot and Egger’s test were not significant) when including data from the studies enrolling patients in the first line setting or in more advanced lines (S1 and S2 Figs). After the one-study-removed procedure, the results of pooled IC ORR did not change, thus confirming that no dominant study was included.

Discussion

Patients with ALK positive NSCLC are generally young and have a substantial risk of developing BMs. With the introduction of ALK inhibitors and the OS increase obtained with these agents, IC control has become more important. In the current paper, we performed a pooled analysis that included data from ALK positive NSCLC patients with BMs receiving treatment with ALK inhibitors, who had been pre-treated or not with radiotherapy and/or chemotherapy. Our results indicate that ALK inhibitors are effective at the brain site. Comparable IC
ORR was observed in patients receiving ALK inhibitors in first or further lines. This efficacy was not dependent by previous radiation.

According to the current guidelines, the treatment strategy suggested for ALK positive patients who develop BMs at the time of diagnosis is systemic therapy with an ALK-inhibitor. Local therapy (radiotherapy or surgery) might be eventually delayed at the onset of symptoms for intracranial disease.

Despite crizotinib activity at brain site, with an IC ORR of 18%, the appearance of BMs is observed in 60% of cases during the course of crizotinib [7]. Crizotinib pharmacokinetic failure is mainly due to its poor blood-brain barrier penetration [27], as it is a substrate of P-glycoprotein and human ATP-binding cassette subfamily efflux transporters.

For these reasons, in the presence of asymptomatic crizotinib brain failure, local treatment and the continuation of crizotinib is generally an accepted strategy, despite no prospective clinical trial has compared this option with the shift to second or third-generation ALK inhibitors at the time of brain progression. In the case of symptomatic multifocal brain progression, local therapy and the shifting to another ALK inhibitor is the preferred choice.

An unanswered clinical question is whether withhold brain radiation in patients receiving second and third generation ALK inhibitors, since these agents penetrate the blood-brain barrier better than crizotinib and offer a significant control of brain disease. This represents a significant challenge, especially considering that whole brain radiotherapy might decrease cognitive function and reduce memory in a young subgroup of patients carrying ALK rearrangement who have a high probability of extended survival (up to four years) after the diagnosis of BMs, as has been recently observed [5]. Further prospective studies are needed to prove that the omission of brain radiotherapy does not negatively impact survival. Only a small fraction of patients (20%-40%) entered into the clinical trials and included in the current meta-analysis were not treated with radiation because in the majority of the studies, the presence of unstable brain lesions was an exclusion criterion. This might have influenced the results of our analysis. Moreover, the activity of ALK inhibitors in the brain was a secondary end point of the trials evaluated, and patients were not stratified according to the number of brain lesions, previous radiation therapy, and the type of radiotherapy used. Furthermore, we have to consider that only a small percentage of the patients had measurable brain lesions (approximately 30%) at the study enrollment. Results from the prospective ongoing NCT02521051 trial, which aims to evaluate the role of alectinib and bevacizumab, and the ASCEND-7 (NCT02336451) trial, designed to assess the efficacy of ceritinib in ALK-positive NSCLC patients with BMs or leptomeningitis who are progressing on crizotinib and who are not treated with radiotherapy, will help to better define the optimal sequence of brain radiation and systemic ALK inhibition.

Our results confirm improved IC control with ceritinib, alectinib, and brigatinib compared with crizotinib. Half the patients included in the ASCEND-1 trial had asymptomatic or controlled BMs [15]. Of the 74 patients evaluable, only 34% had measurable lesions. Comparable results were observed in the phase II ASCEND-2 trial that enrolled 140 NSCLC patients who were progressing on crizotinib [14]. Approximately 70% of the enrolled patients had brain lesions at study entry, 70% of whom had received radiotherapy before starting to use ceritinib. Despite ceritinib being transported by the human ATP-binding cassette sub-family, its binding is stronger to hABCG2 than hABCB1 [28], and a higher expression of hABCB1 has been found in the human blood-brain barrier. This suggests that hABCG2 might have a stronger influence on the accumulation of ceritinib in the brain compared to hABCB1, and indicates that an adequate drug concentration might be obtained. Alectinib is not a substrate of P-glycoprotein, and effective therapeutic concentrations have been measured in the CSF of patients (2.69 nmol/L, which is above the IC50 concentration needed for ALK inhibition) [19]. Brain
tumor regression was observed in mice receiving alectinib and in ALK-positive NSCLC patients not previously treated with brain radiotherapy [19, 20, 22]. There is also evidence that alectinib has activity in patients with leptomeningeal carcinomatosis [29]. A significant reduction in tumor burden in the brain was observed in mice treated with brigatinib compared with those under crizotinib [30]. The efficacy of brigatinib in the CNS was also confirmed in phase I and II clinical trials [24, 25]. According to the available data, the dose of brigatinib influences the IC ORR, with higher efficacy in those patients receiving 180 mg daily.

This is the first pooled-analysis evaluating the efficacy of ALK TKIs in NSCLC patients with BMs using the largest series of data available. Our analysis has several limitations. First, we have not evaluated individual patient data, but we have extracted information from published papers. Second, the quality of the data was heterogeneous, and several relevant types of information, such as the number of BMs, the status of extracranial disease control, the use of salvage therapies, and the health-related quality of life outcomes were not consistently reported. Third, the data refer to both first and further lines of therapy.

Despite the limits discussed above, our results suggest that withholding immediate brain radiotherapy in patients with asymptomatic/oligometastatic BMs and use radiotherapy in case of progression could be a valid option, even though further prospective trials are needed to confirm the efficacy of this strategy. Alectinib is more effective than crizotinib in terms of IC PFS, IC ORR, and overall PFS, and it should be considered as the preferred choice, as confirmed by the ALEX and J-ALEX trials [23, 31].

In conclusion, there is evidence, albeit of limited quality, that ALK positive NSCLC patients with BMs derive significant clinical benefit from ALK inhibitors with or without previous (whole) brain radiotherapy, and the efficacy is similar to that observed for extracranial systemic disease.

Supporting information

S1 Table. PRISMA 2009 checklist.

S1 Fig. Funnel plot for first line studies response rate analysis.

S2 Fig. Funnel plot for second line studies response rate analysis.

Author Contributions

Conceptualization: Fausto Petrelli, Alessandra Bulotta, Mary Cabiddu, Jody Filippo Capitanio, Matteo Brighenti, Vanesa Gregorc.

Data curation: Fausto Petrelli, Chiara Lazzari, Raffaele Ardito, Karen Borgonovo, Alessandra Bulotta, Barbara Conti, Mary Cabiddu, Jody Filippo Capitanio, Matteo Brighenti, Vanesa Gregorc.

Formal analysis: Fausto Petrelli, Chiara Lazzari, Vanesa Gregorc.

Methodology: Fausto Petrelli.

Project administration: Fausto Petrelli.

Resources: Fausto Petrelli.
**Software:** Fausto Petrelli.

**Supervision:** Fausto Petrelli, Jody Filippo Capitanio, Matteo Brighenti, Luca Gianni, Sandro Barni, Vanesa Gregorc.

**Validation:** Fausto Petrelli, Jody Filippo Capitanio, Matteo Brighenti, Mara Ghilardi, Luca Gianni, Sandro Barni, Vanesa Gregorc.

**Visualization:** Fausto Petrelli.

**Writing – original draft:** Fausto Petrelli, Chiara Lazzari, Vanesa Gregorc.

**Writing – review & editing:** Fausto Petrelli, Chiara Lazzari, Mara Ghilardi, Sandro Barni, Vanesa Gregorc.

**References**

1. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004; 304(5676):1497–500. https://doi.org/10.1126/science.1099314 PMID: 15118125

2. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007; 448(7153):561–6. https://doi.org/10.1038/nature05945 PMID: 17625570

3. Shaw AT, Yeap B.Y., Mino-Kenudson M, Digumarthy S.R., Costa D.B., Heist R.S., et al. Clinical features and outcome of patients with non-small cell lung cancer who harbor EML4-ALK. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2009; 27(26):4247–53.

4. Rangachari D, Yamauchi N, VanderLaan PA, Folch E, Mahadevan A, Floyd SR, et al. Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers. Lung Cancer. 2015; 88(1):108–11. https://doi.org/10.1016/j.lungcan.2015.01.020 PMID: 25682925

5. Johung KL, Yeh N, Desai NB, Williams TM, Lautenschlaeger T, Arvold ND, et al. Extended Survival and Prognostic Factors for Patients With ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastasis. J Clin Oncol. 2016; 34(2):123–9. https://doi.org/10.1200/JCO.2015.62.0138 PMID: 26438117

6. Borenstein M, Hedges LV, Higgins JP, Rothstein HR. A basic introduction to fixed-effect and random-effects models for meta-analysis. Res Synth Methods. 2010; 1(2):97–111. https://doi.org/10.1002/jrsm.12 PMID: 26061376

7. Costa DB, Shaw AT, Ou SH, Solomon BJ, Riely GJ, Ahn MJ, et al. Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases. J Clin Oncol. 2015; 33(17):1881–8. https://doi.org/10.1200/JCO.2014.59.0539 PMID: 25624436

8. Lei YY, Yang JJ, Zhong WZ, Chen HJ, Yan HH, Han JF, et al. Clinical efficacy of crizotinib in Chinese patients with ALK-positive non-small-cell lung cancer with brain metastases. J Thorac Dis. 2015; 7(7):1181–8. https://doi.org/10.3978/j.issn.2072-1439.2015.06.04 PMID: 26380734

9. Solomon BJ, Cappuzzo F, Felip E, Blackhall FH, Costa DB, Kim DW, et al. Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014. J Clin Oncol. 2016; 34(24):2858–65. https://doi.org/10.1200/JCO.2015.63.5888 PMID: 27022118

10. Xing P, Wang S, Hao X, Zhang T, Li J. Clinical data from the real world: efficacy of Crizotinib in Chinese patients with advanced ALK-rearranged non-small cell lung cancer and brain metastases. Oncotarget. 2016; 7(51):84666–74. https://doi.org/10.18632/oncotarget.13179 PMID: 27835868

11. Yoshida T, Oya Y, Tanaka K, Shimizu J, Horio Y, Kuroda H, et al. Clinical impact of crizotinib on central nervous system progression in ALK-positive non-small lung cancer. Lung Cancer. 2016; 97:43–7. https://doi.org/10.1016/j.lungcan.2016.04.006 PMID: 27237026

12. Davis KL, Lenz C, Houghton K, Kaye JA. Real-World Clinical Outcomes of Crizotinib Treatment in ALK-Positive Non-Small-Cell Lung Cancer Patients with Brain Metastases. Int J Radiat Oncol Biol Phys. 2017; 98(1):239.

13. Hong X, Chen Q, Ding L, Liang Y, Zhou N, Fang W, et al. Clinical benefit of continuing crizotinib therapy after initial disease progression in Chinese patients with advanced ALK-rearranged non-small-cell lung cancer. Oncotarget. 2017; 8(25):41631–40. https://doi.org/10.18632/oncotarget.15992 PMID: 28427213

14. Crino L, Ahn MJ, De Marinis F, Groen HJ, Wakelee H, Hida T, et al. Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell
ALK inhibitors for NSCLC brain metastases

Lung Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2. J Clin Oncol. 2016; 34(24):2866–73. https://doi.org/10.1200/JCO.2015.65.5936 PMID: 27432917

15. Kim DW, Mehra R, Tan DS, Felip E, Chow LQ, Camidge DR, et al. Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial. Lancet Oncol. 2016; 17(4):452–63. https://doi.org/10.1016/S1470-2045(15)00614-2 PMID: 26973324

16. Bendaly Edmond DAA, Culver Kenneth, Galebach Philip, Bocharova Iryna et al. Treatment patterns and early outcomes of ALK positive Non Small Cell Lung Cancer patients receiving ceritinib: a chart review study. Adv Ther. 2017; 34(1):1145–56. https://doi.org/10.1007/s12325-017-0527-6 PMID: 28405961

17. Shaw AT, Kim TM, Crino L, Gridelli C, Kiura K, Liu G, et al. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2017; 18(7):874–86. https://doi.org/10.1016/S1470-2045(17)30339-X PMID: 28602779

18. Soria JC, Tan DS, Chiari R, Wu YL, Paz-Ares L, Wolf J, et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet. 2017.

19. Gadgeel SM, Gandhi L, Riely GJ, Chiappori AA, West HL, Azada MC, et al. Safety and activity of alec tinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. Lancet Oncol. 2014; 15(10):1119–28. https://doi.org/10.1016/S1470-2045(14)70362-6 PMID: 25153538

20. Gadgeel SM, Shaw AT, Govindan R, Gandhi L, Socinski MA, Camidge DR, et al. Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer. J Clin Oncol. 2016; 34(34):4079–85. https://doi.org/10.1200/JCO.2016.68.4639 PMID: 27863201

21. Metro G, Lunardi G, Bennati C, Chiarini P, Sperduti I, Ricciuti B, et al. Alectinib’s activity against CNS metastases from ALK-positive non-small cell lung cancer: a single institution case series. J Neurooncol. 2016; 129(2):355–61. https://doi.org/10.1007/s11060-016-2184-z PMID: 27324494

22. Tamura T, Kiura K, Seto T, Nakagawa K, Maemondo M, Inoue A, et al. Three-Year Follow-Up of an Alectinib Phase III Study in ALK-Positive Non-Small-Cell Lung Cancer: AF-001 JP. J Clin Oncol. 2017; 35(14):1515–21. https://doi.org/10.1200/JCO.2016.70.5749 PMID: 28396581

23. Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim DW, et al. Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2017.

24. Gettinger SN, Bazhenova LA, Langer CJ, Salgia R, Gold KA, Rosell R, et al. Activity and safety of briga tinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial. Lancet Oncol. 2016; 17(12):1683–96. https://doi.org/10.1016/S1470-2045(16)30392-8 PMID: 27836716

25. Kim DW, Tiseo M, Ahn MJ, Reckamp KL, Hansen KH, Kim SW, et al. Brigitinib in Patients With Crizoti nib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial. J Clin Oncol. 2017; 35(22):2490–8. https://doi.org/10.1200/JCO.2016.71.5904 PMID: 28475456

26. Doherty MK, Korpanty GJ, Tomasini P, Alizadeh M, Jao K, Labbe C, et al. Treatment options for patients with brain metastases from EGFR/ALK-driven lung cancer. Radiother Oncol. 2017; 123(2):195–202. https://doi.org/10.1016/j.radonc.2017.03.007 PMID: 28363487

27. Costa DB, Kobayashi S, Pandya SS, Yeo WL, Shen Z, Tan W, et al. CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol. 2011; 29(15):e443–5. https://doi.org/10.1200/JCO.2010.34.1313 PMID: 27944780

28. Kort A, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH. Brain accumulation of the EML4-ALK inhibitor ceritinib is restricted by P-glycoprotein (P-GP/ABC B1) and breast cancer resistance protein (BCRP/AB CG2). Pharmacol Res. 2015; 102:200–7. https://doi.org/10.1016/j.phrs.2015.09.003 PMID: 26361725

29. Gainor JF, Sherman CA, Willoughby K, Logan J, Kennedy E, Brasilanos PK, et al. Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib. J Thorac Oncol. 2015; 10(2):232–6. https://doi.org/10.1097/JTO.0000000000000455 PMID: 25526238

30. Zhang S, Anjum R, Squillace R, Nadworny S, Zhou T, Keats J, et al. The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models. Clin Cancer Res. 2016; 22(22):5527–38. https://doi.org/10.1158/1078-0432.CCR-16-0569 PMID: 27780853

31. Hida T, Nokihara H, Kondo M, Kim YH, Azuma K, Seto T, et al. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. Lancet. 2017; 390(10089):29–39. https://doi.org/10.1016/S0140-6736(17)30565-2 PMID: 28501140